The role of the bone microenvironment in the pathophysiology and therapeutic management of multiple myeloma: Interplay of growth factors, their receptors and stromal interactions

被引:165
作者
Mitsiades, Constantine S.
Mitsiades, Nicholas S.
Munshi, Nikhil C.
Richardson, Paul G.
Anderson, Kenneth C.
机构
[1] Harvard Univ, Sch Med, Jerome Lipper Multiple Myeloma Ctr, Dept Med Oncol,Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA
关键词
multiple myeloma;
D O I
10.1016/j.ejca.2005.12.025
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The close relationship between the biological behaviour of malignant cells and the local microenvironment where they reside is a feature of diverse neoplasias. Multiple myeloma (MM) is considered a main disease model for the study of such interactions and the mechanisms that can lead to bone-related clinical complications, as well as the role of these interactions in attenuating the activity of conventional anti-MM therapeutics, such as dexamethasone and cytotoxic chemotherapeutics. This review focuses on recent progress in the study of interactions of MM cells with their local microenvironment. Major emphasis is placed on how bone marrow stromal cells (BMSCs) and other normal constituents of the bone marrow milieu promote, through cell adhesion- and cytokine-mediated mechanisms, the ability of MM cells to resist conventional anti-MM therapies. The review also addresses ongoing research into these mechanisms, which has already provided several new molecular targets and corresponding therapeutic strategies, such as the proteasome inhibitor bortezomib and thalidomide derivatives (e.g. lenalidomide), for the management of myeloma. (c) 2006 Elsevier Ltd. All rights reserved.
引用
收藏
页码:1564 / 1573
页数:10
相关论文
共 114 条
[61]   Transcriptional signature of histone deacetylase inhibition in multiple myeloma: Biological and clinical implications [J].
Mitsiades, CS ;
Mitsiades, NS ;
McMullan, CJ ;
Poulaki, V ;
Shringarpure, R ;
Hideshima, T ;
Akiyama, M ;
Chauhan, D ;
Munshi, N ;
Gu, XS ;
Bailey, C ;
Joseph, M ;
Libermann, TA ;
Richon, VM ;
Marks, PA ;
Anderson, KC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2004, 101 (02) :540-545
[62]   Activation of NF-κB and upregulation of intracellular anti-apoptotic proteins via the IGF-1/Akt signaling in human multiple myeloma cells:: therapeutic implications [J].
Mitsiades, CS ;
Mitsiades, N ;
Poulaki, V ;
Schlossman, R ;
Akiyama, M ;
Chauhan, D ;
Hideshima, T ;
Treon, SP ;
Munshi, NC ;
Richardson, PG ;
Anderson, KC .
ONCOGENE, 2002, 21 (37) :5673-5683
[63]   Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer [J].
Mitsiades, CS ;
Koutsilieris, M .
EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2001, 10 (06) :1099-1115
[64]   Biologic sequelae of nuclear factor-κB blockade in multiple myeloma:: therapeutic applications [J].
Mitsiades, N ;
Mitsiades, CS ;
Poulaki, V ;
Chauhan, D ;
Richardson, PG ;
Hideshima, T ;
Munshi, N ;
Treon, SP ;
Anderson, KC .
BLOOD, 2002, 99 (11) :4079-4086
[65]   The mTOR inhibitor RAD001 (everolimus) is active against multiple myeloma cells in vitro and in vivo [J].
Mitsiades, N ;
McMullan, C ;
Poulaki, V ;
Negri, J ;
Raje, N ;
Kumar, S ;
Sikoutri, D ;
Hideshima, T ;
Chauhan, D ;
Richardson, PG ;
Schlossman, RL ;
Kung, AL ;
Lane, H ;
Munshi, NC ;
Anderson, KC ;
Mitsiades, CS .
BLOOD, 2004, 104 (11) :418A-418A
[66]   Molecular sequelae of histone deacetylase inhibition in human malignant B cells [J].
Mitsiades, N ;
Mitsiades, CS ;
Richardson, PG ;
McMullan, C ;
Poulaki, V ;
Fanourakis, G ;
Schlossman, R ;
Chauhan, D ;
Munshi, NC ;
Hideshima, T ;
Richon, VM ;
Marks, PA ;
Anderson, KC .
BLOOD, 2003, 101 (10) :4055-4062
[67]   PHARMACOKINETIC STUDY OF ANTI-INTERLEUKIN-6 (IL-6) THERAPY WITH MONOCLONAL-ANTIBODIES - ENHANCEMENT OF IL-6 CLEARANCE BY COCKTAILS OF ANTI-IL-6 ANTIBODIES [J].
MONTEROJULIAN, FA ;
KLEIN, B ;
GAUTHEROT, E ;
BRAILLY, H .
BLOOD, 1995, 85 (04) :917-924
[68]   Anti-α4 integrin antibody suppresses the development of multiple myeloma and associated osteoclastic osteolysis [J].
Mori, Y ;
Shimizu, N ;
Dallas, M ;
Niewolna, M ;
Story, B ;
Williams, PJ ;
Mundy, GR ;
Yoneda, T .
BLOOD, 2004, 104 (07) :2149-2154
[70]   Vascular endothelial growth factor (VEGF) directly enhances osteoclastic bone resorption and survival of mature osteoclasts [J].
Nakagawa, M ;
Kaneda, T ;
Arakawa, T ;
Morita, S ;
Sato, T ;
Yomada, T ;
Hanada, K ;
Kumegawa, M ;
Hakeda, Y .
FEBS LETTERS, 2000, 473 (02) :161-164